DSLT for Reducing Medication in Glaucoma

Part of paid clinical trials in Largo, Florida.

Sponsor
The Eye Institute of West Florida
Study ID
NCT07390890
Status
Recruiting
Apply to this trial

Conditions

  • Ocular Hypertension
  • Primary Open Angle Glaucoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Voyager DSLT — DEVICE
    Voyager DSLT

Study Details

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Key Dates

Start date
Feb 10, 2026
Status verified
Apr 2026
Primary completion
Jan 26, 2027
Completion
Jan 26, 2027

Study Design

Enrollment
60 participants (estimated)

Primary Outcome Measure

Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP) [ Time Frame: 6 months post-DSLT treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Eye Institute of West FloridaLargoFlorida33770
Renee Bondurant
[email protected]
727-450-4668
Neel Desai, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Largo, FL

By research site
The Eye Institute of West Florida· Largo, FL

Related Studies